Clinical Trials Insight: 700030270

Trial Profile

Clinical Trials Insight: 700030270

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 May 2009

At a glance

  • Drugs PX 12 (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Sponsors Cascadian Therapeutics
  • Most Recent Events

    • 30 May 2009 Status changed from not yet recruiting to suspended. Enrolled has been suspended in all PX 12 trials. Oncothyreon is looking for a partner to continue development with this drug.
    • 01 Feb 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top